When Gilead acquired CAR-T leader Kite Pharma, it made a crucial decision not to fully integrate it. This preserved Kite's distinct, individualized therapy operating model, which is fundamentally different from a traditional "off-the-shelf" drug company, proving a key lesson in M&A strategy for novel platforms.

Gilead recognized that cell therapy is not a 'plug and play' model for big pharma. To preserve Kite's unique operational needs, it remains largely separate. However, integrating general and administrative (G&A) functions opened communication channels, creating a successful hybrid model of operational autonomy and strategic alignment.

Fairfax employs a clever M&A strategy called the "cannibal buy-up." When an asset is too large to acquire outright, they partner with another firm. Later, when financially stronger, they use their capital to buy out the partner's stake, allowing them to gain 100% control of a valuable asset over time.

Gilead's acquisition of Arcellx includes a CVR, promising an extra $5 per share if the drug anita-cel hits a $6B sales target by 2029. This structure mitigates upfront risk for Gilead while allowing Arcellx shareholders to benefit from future commercial success, aligning incentives post-acquisition.

Gilead consistently demonstrates an appetite for high-risk, novel science. From pioneering CAR-T (Kite) and new ADCs (Trodelvi) to its latest T-cell engager deal, the company's acquisition history signals a clear preference for cutting-edge platforms rather than safer, later-in-class assets.

Successful acquisitions don't just benefit the acquired company's investors. These investors often reinvest their profits into new, earlier-stage ventures, providing crucial capital that fuels the entire biotech ecosystem's growth and innovation.

In its acquisition of Bluejay, Mirum employed a creative deal structure combining stock and cash. The stock component ensures Bluejay's shareholders remain invested in the asset's success, while sales milestones de-risk the acquisition for Mirum and allow the selling team to share in future upside, creating a win-win partnership.

Neurix's deals with Sanofi and Gilead involve the partner funding early development through human proof-of-concept, minimizing Neurix's upfront financial risk. Crucially, the deal structure allows Neurix to "opt-in" for a 50/50 profit share in the U.S. later, retaining significant upside on successful programs.

Gilead timed its acquisition of Arcelix to capitalize on peak investor sentiment and a surging stock price, which were driven by its successful HIV franchise. This allowed the company to strategically bolster its smaller oncology pipeline from a position of financial and market strength.